The global impact of the coronavirus pandemic has ignited a renewed focus on emerging and re-emerging infectious diseases.
FDA lifts clinical hold on Mersana’s STING agonist, PhI starting dose lowered after patient death
The FDA has lifted the full clinical hold on Mersana Therapeutics’ STING-targeted antibody-drug conjugate on the back of the company making Phase I study dosing